Human stem and progenitor cells have been shown to engraft in the marrow and spleen of sublethally irradiated NOD/SCID, sCID, Bg Nude/XID, NOD/SCID r chain""" (NSG) mice and in fetal organs xenografted in NOD/SCID (SCID/Hu) mice [1]. In some studies, optimal engraftment required administration of specific recombinant human growth factors [2]. Nevertheless, the demonstration of multilineage hematopoiesis in NOD/SCID mice transplanted with isolated human CD34+/CD38- "stem" cells supports the notion that xenogeneic transplantation in immunodeficient mice may serve as a surrogate model for human transplantation. Given the importance of preclinical in vivo models, the purpose of Core E is to provide CCEH members as well as other UW and FHCRC investigators with the resources and expertise needed to execute xenografting studies in immune deficient mice. The majority of studies involve analysis of hematopoietic reconstituting ability or immune function of defined populations of cells from humans, non-human primates, and dogs. Protocols have also been developed for evaluating the teratoma generating potential of ESC and iPSC, as well as the engraftment and regenerative potential of their derived progeny. Specifically Core E provides: 1) age appropriate NOD/SCID mice through an in-house breeding program, 2) expert consultation on experimental design, 3) help with obtaining lACUC approval, and 4) assistance with and/or full responsibility for conditioning and injecting mice, as well as sampling tissues from live and euthanized animals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK056465-15
Application #
8566029
Study Section
Special Emphasis Panel (ZDK1-GRB-G)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$126,557
Indirect Cost
$53,210
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
King, Bryan; Boccalatte, Francesco; Moran-Crusio, Kelly et al. (2016) The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol 17:1312-1321
Rosinski, Steven Lawrence; Stone, Brad; Graves, Scott S et al. (2016) Minor Antigen Vaccine-Sensitized DLI: In Vitro Responses Do Not Predict In Vivo Effects. Transplant Direct 2:e71
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Blau, C Anthony; Ramirez, Arturo B; Blau, Sibel et al. (2016) A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. J Natl Compr Canc Netw 14:8-17
Turtle, Cameron J; Hanafi, Laïla-Aïcha; Berger, Carolina et al. (2016) Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8:355ra116
Su, Wei; Kang, John; Sopher, Bryce et al. (2016) Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem 136 Suppl 1:49-62
Yeung, Cecilia C S; Deeg, H Joachim; Pritchard, Colin et al. (2016) Jumping translocations in myelodysplastic syndromes. Cancer Genet 209:395-402
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173
Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46
Toledo, Chad M; Ding, Yu; Hoellerbauer, Pia et al. (2015) Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 13:2425-39

Showing the most recent 10 out of 250 publications